Status: Recruiting
Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma
The study included 298 RCC patients who were at high risk for recurrence after nephrectomy (T2G3-4 or T3-4 or N1). They were randomly divided to receive axitinib plus PD-1 + surgery or surgery alone at a ratio of 1:1, so as to determine the efficacy of the neoadjuvant combination of axitinib plus PD-1.
Participants needed: 298
Trial details
Phase: Phase 3Age: 18-80Biological sex: AllType: InterventionalSponsor: ZHOU FANGJIANUpdated: Mar 17, 2026Locations: 8
Eligibility criteria
Voluntarily agree to participate in this study and sign the informed consent for... [+4]
With distant metastasis [+5]